14 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection.
University of California
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Panjab University
Examination of multiple Trypanosoma cruzi targets in a new drug discovery approach for Chagas disease.
Universidad De Navarra
Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors.
Irbm
Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
"Sapienza" Universit£
A new chemotype with promise against Trypanosoma cruzi.
University of Nebraska Medical Center
Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents.
Scripps Florida
Structurally simple inhibitors of lanosterol 14alpha-demethylase are efficacious in a rodent model of acute Chagas disease.
University of Washington
Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.
Vanderbilt University School of Medicine
2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease.
University of Dundee
Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
Instituto Oswaldo Cruz
Bacterial topoisomerase I inhibitors with antibacterial activity
The Florida International University Board of Trustees
Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
Galderma Research & Development